Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732471 | SCV000860435 | pathogenic | not provided | 2018-03-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001222307 | SCV001394401 | pathogenic | Fabry disease | 2019-07-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in GLA are known to be pathogenic (PMID: 10666480, 12175777). This variant has been observed in individuals affected with Fabry disease (PMID: 9100224, 23935525). ClinVar contains an entry for this variant (Variation ID: 596584). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gly261Valfs*8) in the GLA gene. It is expected to result in an absent or disrupted protein product. |
Revvity Omics, |
RCV000732471 | SCV002024282 | pathogenic | not provided | 2019-05-27 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001222307 | SCV002054408 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |